1 / 7

Helping to Solve a Grave Problem

Helping to Solve a Grave Problem. Onset Severe Symptoms. Aortic stenosis is life threatening and progresses rapidly Survival after onset of symptoms is 50% at 2 years and 20% at 5 years 1 “Surgical intervention [for severe AS] should be performed promptly once even…minor symptoms occur” 1.

clarke
Download Presentation

Helping to Solve a Grave Problem

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Helping to Solve a Grave Problem Onset Severe Symptoms • Aortic stenosis is life threatening and progresses rapidly • Survival after onset of symptoms is 50% at 2 years and 20% at 5 years1 • “Surgical intervention [for severe AS] should be performed promptly once even…minor symptoms occur”1 100 80 Angina Latent Period (Increasing Obstruction, Myocardial Overload) Syncope Failure 60 Survival, % 40 0 2 4 6 Average Survival, y 20 0 40 50 60 70 80 Age, y

  2. Addressing a Serious Unmet Need • At least 40% of patients with severe aortic stenosis (AS) do not have an AVR2-8 No AVR Aortic Valve Replacement (AVR) Patients, % 1999 2005 2006 2009 2009 2010 2006

  3. Sobering Perspective 5-Year Survival Survival, % * * * * * † * National Institutes of Health. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Stat Fact Sheets. http://seer.cancer.gov/statfacts/. Accessed November 16, 2010. † Using constant hazard ratio. Data on file, Edwards Lifesciences LLC. Analysis courtesy of Murat Tuczu.

  4. The PARTNER Trial Protocol Severe Symptomatic Native Aortic Valve Stenosis Yes No Assessment Operability 2 Cohorts Individually Powered (N = 1,057) Cohort A (n = 699) Cohort B (n = 358) Cohort A Yes Assessment Transfemoral Access No Yes Assessment Transfemoral Access No TF (n = 492) TA (n = 207) Not in Study 1:1 Randomization 1:1 Randomization 1:1 Randomization TF TAVR (n = 244) AVR (Control) (n = 248) TA TAVR (n = 104) AVR (Control) (n = 103) TF TAVR (n = 179) Standard Therapy (Control) (n = 179) vs vs vs Primary Endpoint: All-Cause Mortality OverLength of Trial (Superiority) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority) Primary Endpoint: All-Cause Mortality (1 yr)(Non-inferiority) TA, transapical; TF, transfemoral.

  5. Edwards SAPIEN THV Delivered QOL Benefits 100 Standard Therapy 80 60 40 20 0 Edwards SAPIEN THV MCID = 5 points • Improvement in quality of life KCCQ Score (Mean) ∆ = 13.9P < .001 ∆ = 24.5P < .001 0 2 4 6 8 10 12 Months MCID, minimum clinically important difference.

  6. Edwards SAPIEN THV Delivered 20% Reduction in Mortality Edwards SAPIEN THV Standard Therapy • ∆ at 1 yr = 20.0%NNT = 5.0 pts 100 80 • 20% absolute reduction in mortality at 1 year 50.7% All-Cause Mortality, % 60 • HR [95% CI] =0.51 [0.38, 0.68] • P (log rank) < .0001 40 30.7% 20 Months 0

More Related